Celgene's apremilast improves DMARD-naïve psoriatic arthritis; reimbursement uncertain
This article was originally published in Scrip
Executive Summary
The first detailed results from Celgene's Phase III PALACE 4 clinical trial show that apremilast improves the signs and symptoms of psoriatic arthritis in patients who've never taken disease-modifying anti-rheumatic drugs (DMARDs), but it may be difficult to convince health care payers to reimburse the drug's costs in the absence of treatment with older therapies.